General Information of Drug (ID: DM0BL2G)

Drug Name
Mitiperstat Drug Info
Synonyms
Mitiperstat; AZD4831; Mitiperstat [INN]; AZD-4831; S6GYK3X4QQ; 1933460-19-5; UNII-S6GYK3X4QQ; AZD-4831 [WHO-DD]; 1-((2-((1R)-1-Aminoethyl)-4-chloro-phenyl)methyl)-2-thioxo-5hpyrrolo(3,2-d)pyrimidin-4-one; 4H-Pyrrolo(3,2-d)pyrimidin-4-one, 1-((2-((1R)-1-aminoethyl)-4-chlorophenyl)methyl)-1,2,3,5-tetrahydro-2-thioxo-; 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-1,2,3,5-tetrahydro-2-thioxo-; Alternative Preparation; MITIPERSTAT [USAN]; Azd 4831; CHEMBL5095218; SCHEMBL17782047; GTPL12154; AZD 4831 [WHO-DD]; BHKKSKOHRFHHIN-MRVPVSSYSA-N; BDBM312172; GLXC-26157; EX-A7129; compound 16 [PMID: 36005476]; HY-145581; CS-0376445; US9616063, 3; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1H,2H,3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-{2-[(1R)-1-Aminoethyl]-4-chlorobenzyl}-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
Indication
Disease Entry ICD 11 Status REF
Heart failure with preserved ejection fraction BD11.0 Phase 2/3 [1]
Chronic obstructive pulmonary disease CA22 Phase 2 [2]
Cross-matching ID
PubChem CID
121362450
TTD Drug ID
DM0BL2G

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Myeloperoxidase (MPO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
E-101 DMM1YC4 Infectious disease 1A00-CA43.1 Phase 3 [4]
AZD-3241 DMANC59 Parkinson disease 8A00.0 Phase 2 [5]
AZD4831 DMRP3N8 Heart failure BD10-BD13 Phase 1 [6]
AZD5904 DM8SCON Chronic obstructive pulmonary disease CA22 Discontinued in Phase 1 [7]
INV-311 DM8BZVI Inflammation 1A00-CA43.1 Investigative [8]
4-aminobenzoic acid hydrazide DMP2GN7 Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Myeloperoxidase (MPO) TTVCZPI PERM_HUMAN Inhibitor [3]

References

1 ClinicalTrials.gov (NCT04986202) A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05492877) A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of Mitiperstat (AZD4831), for 12-24 Weeks, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
3 Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction. J Med Chem. 2022 Sep 8;65(17):11485-11496.
4 In vitro antibacterial activity of E-101 Solution, a novel myeloperoxidase-mediated antimicrobial, against Gram-positive and Gram-negative pathogens. J Antimicrob Chemother. 2011 Feb;66(2):335-42.
5 Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of AstraZeneca (2009).
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2789).
9 Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. J Pharmacol Exp Ther. 2010 Nov;335(2):389-400.